FATE
Income statement / Annual
Last year (2023), Fate Therapeutics, Inc.'s total revenue was $63.53 M,
a decrease of 34.03% from the previous year.
In 2023, Fate Therapeutics, Inc.'s net income was -$160.93 M.
See Fate Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$63.53 M
|
$96.30 M
|
$55.85 M
|
$31.43 M
|
$10.68 M
|
$4.74 M
|
$4.11 M
|
$4.40 M
|
$2.43 M
|
$0.00
|
| Cost of Revenue |
$161.70 M |
$13.76 M |
$5.85 M |
$125.62 M |
$87.77 M |
$56.02 M |
$34.36 M |
$26.45 M |
$19.86 M |
$16.43 M |
| Gross Profit |
-$98.16 M |
$82.54 M |
$50.00 M |
-$94.19 M |
-$77.09 M |
-$51.28 M |
-$30.25 M |
-$22.05 M |
-$17.43 M |
-$16.43 M |
| Gross Profit Ratio |
-1.55 |
0.86 |
0.9 |
-3 |
-7.22 |
-10.82 |
-7.37 |
-5.01 |
-7.17 |
0 |
| Research and Development
Expenses |
$172.60 M
|
$320.45 M
|
$215.52 M
|
$125.62 M
|
$87.77 M
|
$56.02 M
|
$34.36 M
|
$26.45 M
|
$19.86 M
|
$16.44 M
|
| General & Administrative
Expenses |
$81.45 M
|
$84.23 M
|
$57.32 M
|
$33.90 M
|
$23.64 M
|
$15.81 M
|
$11.87 M
|
$9.91 M
|
$10.35 M
|
$8.47 M
|
| Selling & Marketing
Expenses |
-$2.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$79.45 M
|
$84.23 M
|
$57.32 M
|
$33.90 M
|
$23.64 M
|
$15.81 M
|
$11.87 M
|
$9.91 M
|
$10.35 M
|
$8.47 M
|
| Other Expenses |
$0.00 |
$20.82 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$254.04 M |
$404.69 M |
$272.84 M |
$159.52 M |
$111.41 M |
$71.83 M |
$46.23 M |
$36.37 M |
$30.21 M |
$24.90 M |
| Cost And Expenses |
$254.04 M |
$404.69 M |
$272.84 M |
$159.52 M |
$111.41 M |
$71.83 M |
$46.23 M |
$36.37 M |
$30.21 M |
$24.90 M |
| Interest Income |
$17.19 M |
$5.84 M |
$1.31 M |
$2.40 M |
$4.33 M |
$2.19 M |
$559,000.00 |
$138,000.00 |
$10,000.00 |
$2,000.00 |
| Interest Expense |
$0.00 |
$5.84 M |
$0.00 |
$0.00 |
$1.75 M |
$1.70 M |
$1.27 M |
$1.64 M |
$2.22 M |
$549,000.00 |
| Depreciation &
Amortization |
$18.28 M
|
$13.76 M
|
$5.85 M
|
$3.09 M
|
$2.19 M
|
$1.20 M
|
$971,000.00
|
$881,000.00
|
$687,000.00
|
$496,000.00
|
| EBITDA |
-$172.23 M
|
-$294.63 M
|
-$211.14 M
|
-$125.00 M
|
-$94.20 M
|
-$63.70 M
|
-$40.71 M
|
-$30.94 M
|
-$27.09 M
|
-$24.41 M
|
| EBITDA Ratio |
-2.71 |
-3.2 |
-3.86 |
-4 |
-9.03 |
-13.69 |
-10.12 |
-7.23 |
-11.42 |
0 |
| Operating Income Ratio
|
-3
|
-3.2
|
-3.89
|
-4.07
|
-9.43
|
-14.15
|
-10.26
|
-7.26
|
-11.43
|
0
|
| Total Other
Income/Expenses Net |
$29.58 M
|
$26.67 M
|
$4.84 M
|
-$45.30 M
|
$2.58 M
|
$494,000.00
|
-$827,000.00
|
-$1.50 M
|
-$2.21 M
|
-$979,000.00
|
| Income Before Tax |
-$160.93 M |
-$281.72 M |
-$212.15 M |
-$173.39 M |
-$98.15 M |
-$66.60 M |
-$42.95 M |
-$33.46 M |
-$29.99 M |
-$25.88 M |
| Income Before Tax Ratio
|
-2.53
|
-2.93
|
-3.8
|
-5.52
|
-9.19
|
-14.05
|
-10.46
|
-7.6
|
-12.34
|
0
|
| Income Tax Expense |
$0.00 |
-$26.67 M |
-$5.85 M |
-$3.09 M |
-$441,000.00 |
$2.19 M |
$297,000.00 |
-$743,000.00 |
-$677,000.00 |
$53,000.00 |
| Net Income |
-$160.93 M |
-$255.06 M |
-$206.30 M |
-$170.30 M |
-$97.71 M |
-$66.60 M |
-$42.95 M |
-$33.46 M |
-$29.99 M |
-$25.88 M |
| Net Income Ratio |
-2.53 |
-2.65 |
-3.69 |
-5.42 |
-9.15 |
-14.05 |
-10.46 |
-7.6 |
-12.34 |
0 |
| EPS |
-1.64 |
-2.63 |
-2.18 |
-2.07 |
-1.43 |
-1.19 |
-1.02 |
-1.05 |
-1.18 |
-1.27 |
| EPS Diluted |
-1.64 |
-2.63 |
-2.18 |
-2.07 |
-1.43 |
-1.19 |
-1.02 |
-1.05 |
-1.18 |
-1.27 |
| Weighted Average Shares
Out |
$98.41 M
|
$96.83 M
|
$94.75 M
|
$82.39 M
|
$68.19 M
|
$56.20 M
|
$41.98 M
|
$31.75 M
|
$25.48 M
|
$20.45 M
|
| Weighted Average Shares
Out Diluted |
$98.41 M
|
$96.83 M
|
$94.75 M
|
$82.39 M
|
$68.19 M
|
$56.20 M
|
$41.98 M
|
$31.75 M
|
$25.48 M
|
$20.45 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
